Currently, an estimated 387 million people have diabetes worldwide, with Type 2 making up about 90% of the cases. This represents 8.3% of the adult population with equal rates in both women and men. From past few years, diabetes is estimated to have resulted in 1.5 to 4.9 million deaths each year. Diabetes at least doubles a person’s risk of death. The number of people with diabetes is expected to rise to 592 million by 2035.
NMT Pharma has developed an innovative administration route of insulin via pulmonary inhalation. Insulin is a key treatment of diabetes with market share of more than 50%. Insulin being a polypeptide cannot be ingested by oral, and the conventional injection is a very inconvenient and painful experience to long-term and frequent patients. The inhalable insulin has the benefits of fast acting, easy to use and high patient compliance. NMT Pharma’s inhalable insulin can achieve more than 90% of the insulin being emitted into the target lung area for absorption into blood vessels to regulate sugar in our body.